There are no proven peptides for stroke recovery in the US. The most rigorously tested, nerinetide, failed both of its large trials: good outcomes at 90 days were 61.4% versus 59.2% on placebo in ESCAPE-NA1 and 45% versus 46% in ESCAPE-NEXT.[4][5] Cerebrolysin improved arm function in two small rehabilitation trials,[8] but a Cochrane review of acute stroke trials found no effect on death and a possible rise in non-fatal serious adverse events.[10] Semax has only small Russian studies.[13]
This guide grades the evidence. For related topics, see our nootropic peptides hub.
Evidence at a glance
| Peptide or treatment | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Clot-busting drugs and clot removal; rehabilitation | FDA-approved for this use (drugs) | Standard emergency care and recovery[2][3] | Approved (not peptides) | n/a |
| Nerinetide | Human RCTs | No benefit in ESCAPE-NA1, ESCAPE-NEXT or FRONTIER[4][5][6] | Not approved | n/a |
| Cerebrolysin (rehabilitation) | Human RCTs (small) | Better arm function in CARS 1 and 2[8] | Not approved | Cerebrolysin |
| Cerebrolysin (acute stroke) | Human RCTs | No effect on death; possible more non-fatal serious events[10] | Not approved | Cerebrolysin |
| Semax | Small human studies | Faster recovery reported in Russian study[13] | Not approved | Semax |
Start with emergency care and rehabilitation
For ischemic stroke, caused by a blocked artery, US guidelines support clot-busting medicine for eligible patients within hours of onset and mechanical clot removal (thrombectomy) for large blockages.[2] After the emergency, the American Heart Association recommends organized, multidisciplinary rehabilitation, including physical, occupational and speech therapy, to rebuild movement, daily skills and communication.[3] Preventing another stroke through blood pressure, cholesterol, diabetes and heart-rhythm care is part of recovery.
Nerinetide: the most rigorous test, and it failed
Nerinetide is a 20-amino-acid peptide designed to protect brain cells during the minutes and hours when blood flow is cut off. It worked in animal models, so it was tested in people having clot removal.
- ESCAPE-NA1 (2020): 1,105 patients in 8 countries got a single IV dose or placebo. Good outcomes (little or no disability at 90 days) were 61.4% versus 59.2%, not a significant difference. The drug seemed to work less in people who also got the clot-buster alteplase.[4]
- ESCAPE-NEXT (2025): to test that idea, 850 patients who did not get a clot-buster were enrolled. Good outcomes were 45% on nerinetide and 46% on placebo. Serious side effects were similar.[5]
- FRONTIER (2025): paramedics gave nerinetide or placebo in the ambulance to 532 people with suspected stroke, a median of 64 minutes after onset. Overall, 57% versus 58% had a good outcome. A subgroup who went on to get clot treatment seemed to benefit, which the authors said needs confirmation.[6]
Nerinetide is not approved anywhere we could find. It remains a research drug.
Cerebrolysin: used abroad, debated evidence
Cerebrolysin is an injected peptide mix made from pig brain. It is used for stroke in parts of Europe and Asia, but its maker says it is not registered with FDA or approved for sale in the US.[12]
For rehabilitation:
- CARS (2016): stroke patients got 30 mL of Cerebrolysin or saline daily for 21 days, starting 24 to 72 hours after the stroke, along with standard rehabilitation. Arm function at 90 days was better with Cerebrolysin. The authors called the study exploratory and small.[7]
- CARS 1 and 2 combined (2017): in 442 patients, Cerebrolysin improved arm function and early stroke scores, with safety similar to placebo.[8]
- European guideline (2021): the European Academy of Neurology and its neurorehabilitation partner recommended Cerebrolysin, at 30 mL daily for at least 10 days, for early motor rehabilitation.[11]
For acute stroke:
- Asian acute stroke trial (2012): in 1,070 patients treated within 12 hours, the main outcome showed no difference. A post hoc look at severe strokes showed a trend toward benefit.[9]
- Cochrane review (2023): across 7 trials and 1,773 people, Cerebrolysin or similar products probably made little or no difference to death, and moderate-certainty evidence suggested more non-fatal serious adverse events (risk ratio 2.39). The reviewers noted the manufacturer supported three of the multicenter trials.[10]
Semax: Russian data only
Semax is a nasal peptide prescribed for stroke in Russia. In a Russian study of 110 patients in rehabilitation after ischemic stroke, those given Semax had higher blood levels of the growth factor BDNF and faster gains on a daily-living scale.[13] The study, as described, was not a placebo-controlled trial. FDA staff reviewed Semax in 2026 and recommended against allowing it in pharmacy compounding.[14] See Selank vs Semax.
What’s next
A multicenter trial led by Chang Gung Memorial Hospital plans to test Cerebrolysin after clot removal in people treated in an extended time window, enrolling 100 patients; it was listed as not yet recruiting in October 2026.[15] For nerinetide, the ESCAPE-NEXT and FRONTIER authors said further trials would be needed to find the right timing and the patients most likely to benefit.[5][6]
Safety notes
In the trials described here, Cerebrolysin was given as daily IV infusions for 10 to 21 days.[7][11] Products sold online as “research peptides,” including nasal Semax, are not checked for purity or dose. Many people take blood thinners and blood pressure medicines after a stroke, and interactions with unapproved peptides have not been studied.
Questions to ask your stroke team
- What rehabilitation do I need, and how intensive should it be?
- What is my plan to prevent another stroke?
- Are there clinical trials I could join?
For related reading, see peptides for TBI and concussion, peptides for Alzheimer’s and Parkinson’s and best peptides for cognition.
